First-in-class life-saving drugs

Results in severe pneumonia patients ranked “a medical breakthrough”: The Lancet Infectious Diseases
(Laterre et al. 2019; Pletz et al. 2019)

First-in-class life-saving drugs

Results in severe pneumonia patients ranked “a medical breakthrough”.
The Lancet Infectious Diseases (Laterre et al. 2019; Pletz et al. 2019)

CAL02

Novel first-in-class anti-virulence agent for the treatment of severe community-acquired bacterial pneumonia.

The unique therapeutic approach of CAL02 consists in using liposomes engineered to neutralize virulence effectors playing a critical role in the development of organ failure and fatal complications in severe infections.

Received FDA Fast-Track and Qualified Infectious Disease Product (QIDP) designations.

Global Phase 2 clinical study underway.

Combioxin entered into a worlwide licensing agreement with Eagle Pharmaceuticals for the commercial rights to CAL02.

Visit Eagle Pharmaceutical’s website.

.

Selected publications

Critical parameters for the development of novel therapies for severe and resistant infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug. Azeredo da Silbeira S and Shorr A. Antibiotics, 2020; 9, 94.

CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial. Laterre PF et al. Lancet Infect Dis. 2019; 19(6):620-630.

One step closer to precision medicine for infectious diseases. Pletz MW et al. Lancet Infect Dis. 2019; 19(6):564-565.

CAL02 liposomes and other anti-toxins: A new generation of anti-infectives. Azeredo da Silveira S and Perez A. Clin Pulm Med 2018; 25(3):84-88.

Liposomal therapy attenuates dermonecrosis induced by community-associated methicillin-resistant Staphilococcus aureus by targeting a-type phenol soluble modulins and a-hemolysin. Wolfmeier H et al. EbioMedicine 2018; 33:211-217.

Clinical Streptococcus pneumoniae isolates induce differing CXCL8 responses from human nasopharyngeal epithelial cells which are reduced by liposomes. Baumgartner D et al. BMC Microbiology, 2016; 16:154.

Precision medicine for the treatment of severe pneumonia in intensive care. Rello J and Perez A. Expert Review of Respiratory Medicine 2016; 10(3):297-316.

Liposomes as novel anti-infectives targeting bacterial virulence factors Azeredo da Silveira S and Perez A. Expert Review of Anti-infective Therapy 2015; 13(5):531-3.

Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice. Henry BD et al. Nature Biotechnology 2015; 33(1):81-8.